Universal, zero-footprint viewers help clinicians streamline diagnosis, improve result turnaround time and facilitate communication and sharing with patients. How “universal” must these viewers be to truly deliver on their promises? Here are five key criteria to look for before deploying a universal, zero-footprint viewer.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.